It goes without saying, 2020 was a year with major challenges and disruptions. However, it was also a year of growth and new opportunities for the biotechnology industry and for Somatek.
In the summer of 2020, Somatek moved into newly renovated laboratory facilities in San Diego California, significantly increasing both lab and office space. In addition, Somatek purchased new capital equipment to support expanding services in the areas of process and assay development to support and enable the manufacture of proteins and viruses.
While Somatek’s laboratory services have been expanding, so has its core business of providing CMC consulting and project oversight of CROs and CDMOs. In 2020, one program supported by Somatek entered phase III clinical trials while two others entered phase I.
Last year Gina Cruz-Aranda and David Ingamells joined the Somatek team. Gina is Head of Operations and David is Somatek’s newest Biologics Manufacturing and Project Management Consultant. In addition, Somatek welcomed two new research associates focusing on laboratory production, purification, and analytics.
Having signed two new major clients and delivering ongoing support to five established clients, Somatek is well positioned for 2021 and the team is excited to be working with its clients and collaborators on the development and creation of next generation biopharmaceuticals, diagnostics, and research reagents.